For the quarter ending 2025-09-30, SRPT made $399,356,000 in revenue. -$179,676,000 in net income. Net profit margin of -44.99%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 399,356,000 | 611,091,000 | 744,856,000 | 478,269,000 |
| Cost of sales (excluding amortization of in-licensed rights) | 150,775,000 | 152,558,000 | 137,564,000 | 75,802,666.667 |
| Research and development | 218,890,000 | 204,392,000 | 773,448,000 | 193,346,333.333 |
| Selling, general and administrative | 91,893,000 | 137,897,000 | 133,629,000 | 143,224,000 |
| Restructuring charges | 40,510,000 | - | - | - |
| Amortization of in-licensed rights | 677,000 | 667,000 | 601,000 | 601,000 |
| Total cost and expenses | 502,745,000 | 495,514,000 | 1,045,242,000 | 412,974,000 |
| Operating (loss) income | -103,389,000 | 115,577,000 | -300,386,000 | 65,295,000 |
| Loss on debt extinguishment | -138,613,000 | - | - | - |
| Other income, net | 47,953,000 | 38,061,000 | -83,132,000 | 10,294,333.333 |
| Total other (loss) income, net | -90,660,000 | - | - | 10,294,333.333 |
| (loss) income before income tax (benefit) expense | -194,049,000 | 153,638,000 | -383,518,000 | 75,589,333.333 |
| Income tax (benefit) expense | -14,102,000 | -43,254,000 | 63,990,000 | 8,380,000 |
| Net (loss) income | -179,947,000 | 196,892,000 | -447,508,000 | 67,209,333.333 |
| Unrealized gains on investments, net of tax | 271,000 | -85,000 | - | - |
| Total other comprehensive income | 271,000 | -85,000 | - | - |
| Comprehensive (loss) income | -179,676,000 | 196,807,000 | - | - |
| Basic | 100,237,000 | 98,005,000 | 97,362,000 | -105,000 |
| Diluted | -1.8 | 1.89 | -4.6 | 0.667 |
| Diluted | 100,237,000 | 106,623,000 | 97,362,000 | 2,475,666.667 |
| Earnings per share, basic | -1.8 | 2.01 | -4.6 | 0.707 |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)